Spyre Therapeutics, Inc. SYRE Derivative Liability, Noncurrent
Derivative Liability, Noncurrent at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesNoncurrent.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s derivative liability, noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s derivative liability, noncurrent?
- Spyre Therapeutics, Inc. (SYRE) reported derivative liability, noncurrent of $6.69M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s derivative liability, noncurrent changed year-over-year?
- Spyre Therapeutics, Inc.'s derivative liability, noncurrent decreased by 59.4% year-over-year, from $16.49M to $6.69M.